(Q57913848)

2

0 references

Claudia Chalk

3

0 references

Bruce C Trapnell

4

0 references

Jost Langhorst

5

0 references

Lee A Denson

6

0 references

Dirk Foell

The American Journal of Gastroenterology

7

0 references

language of work or name

English

0 references

publication date

22 October 2013

0 references

published in

0 references

volume

108

0 references

issue

12

0 references

page(s)

1901-1910

0 references

cites work

Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

GM-CSF: a role in immune and inflammatory reactions in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Phase I trial of sargramostim in pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Anti-interleukin-8 autoantibody:interleukin-8 immune complexes in acute lung injury/acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Immunodeficiency secondary to anticytokine autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Improving Relapse Prediction in Inflammatory Bowel Disease by Neutrophil-Derived S100A12

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Biologic therapy of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

New therapies for inflammatory bowel disease: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Update of fecal markers of inflammation in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.360